Bruker (NASDAQ:BRKR) VP Sells $105,740.00 in Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the sale, the vice president owned 134,806 shares in the company, valued at $7,127,193.22. The trade was a 1.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Bruker Trading Down 2.6%

Bruker stock opened at $61.39 on Friday. The firm has a market cap of $9.35 billion, a price-to-earnings ratio of -87.70, a price-to-earnings-growth ratio of 1.93 and a beta of 1.26. Bruker Corporation has a 1 year low of $30.09 and a 1 year high of $65.30. The firm’s 50 day moving average price is $58.17 and its two-hundred day moving average price is $49.90. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.92 and a current ratio of 1.85.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The company had revenue of $838.50 million during the quarter, compared to the consensus estimate of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, research analysts predict that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, September 21st. Bruker’s payout ratio is presently -28.57%.

Analysts Set New Price Targets

Several research firms have recently weighed in on BRKR. Stifel Nicolaus set a $50.00 target price on shares of Bruker in a research report on Wednesday, August 5th. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Zacks Research downgraded shares of Bruker from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 2nd. Guggenheim increased their target price on Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a report on Monday, June 29th. Finally, UBS Group started coverage on Bruker in a research report on Wednesday, September 9th. They set a “neutral” rating and a $65.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $57.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of BRKR. Pallas Capital Advisors LLC bought a new stake in shares of Bruker in the 2nd quarter valued at approximately $570,746,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Bruker in the second quarter valued at approximately $169,899,000. Franklin Resources Inc. grew its position in Bruker by 317.7% in the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after acquiring an additional 1,756,460 shares in the last quarter. Primecap Management Co. CA acquired a new position in shares of Bruker during the 2nd quarter worth $53,145,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Bruker during the 2nd quarter valued at $44,839,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.